FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.

Personeni, Nicola

FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study. [electronic resource] - Clinical colorectal cancer Sep 2015 - 162-9 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1938-0674

10.1016/j.clcc.2015.02.006 doi


Aged
Antineoplastic Combined Chemotherapy Protocols--adverse effects
Camptothecin--adverse effects
Cetuximab--administration & dosage
Colorectal Neoplasms--drug therapy
Disease-Free Survival
Female
Fluorouracil--adverse effects
Gene Expression Regulation, Neoplastic
Humans
Leucovorin--adverse effects
Male
Middle Aged
Mutation
Neoplasm Metastasis
PTEN Phosphohydrolase--genetics
Prognosis
Prospective Studies
Proto-Oncogene Proteins B-raf--genetics
Proto-Oncogene Proteins c-met--genetics
Proto-Oncogene Proteins p21(ras)--genetics